Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.33 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820948 | 0.84 | PDE2A (0.41) | PDE2AMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL12820956 | 0.77 | PDE2A (0.41) | PDE2AMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL14725444 | 0.72 | PI4KA (0.39) | PDE2AMEN1TSHRKMT2AXDH | |
| SCHEMBL26349041 | 0.71 | PDE9A (0.34) | PDE2AALDH1A1PARP1PDE9AKDM4E | |
| SCHEMBL14725428 | 0.69 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL25467968 | 0.68 | CDK4 (0.37) | TYMSPARP1 | |
| SCHEMBL14725449 | 0.68 | PDE2A (0.36) | PDE2ATYMSALDH1A1HPGD | |
| SCHEMBL26348852 | 0.67 | KDM4E (0.46) | PDE2AALDH1A1PDE9AKDM4EMEN1 | |
| SCHEMBL27407446 | 0.66 | SRC (0.32) | — | |
| SCHEMBL24905821 | 0.65 | PDE2A (0.41) | PDE2AMTORRICTORRPTORMAPKAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9566340-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2016-04-14 | — | — | US | disclosed |
| US-9198972-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | PDE2A 4619/4885MTOR 3083/4885RICTOR 2081/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | PDE2A 4600/4885MTOR 3280/4885RICTOR 2302/4885 |
| US-20160101189-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | PDE2A 4600/4885MTOR 3280/4885RICTOR 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.